CriticalPharmacokinetic enhancer (booster) for antiretroviral therapy×Antiepileptics. Barbiturates
Updated · Methodology
Mechanism
Phenobarbital is a potent inducer of drug-metabolising enzymes (cytochromes P450 and glucuronosyltransferases) and of the transporter P-glycoprotein (P-gp), so it can speed up the elimination of many drugs and weaken their effect (phenobarbital summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The cobicistat SmPC and label list phenobarbital among strong CYP3A inducers, and CYP3A metabolises both cobicistat and the atazanavir or darunavir it boosts (cobicistat SmPC, European Medicines Agency, EMA, and label, US Food and Drug Administration, FDA). The levels of cobicistat and of the boosted drug may fall, human immunodeficiency virus (HIV) treatment may lose its effect, and the virus may become resistant (cobicistat SmPC, EMA). For the darunavir/cobicistat/emtricitabine/tenofovir alafenamide tablet, the SmPC also expects phenobarbital to reduce the absorption of tenofovir alafenamide by inducing P-gp (SmPC of this product, EMA). The documents do not describe any effect of cobicistat on phenobarbital.
Symptoms
The fall in the levels of cobicistat and of the boosted drug causes no symptoms by itself. The main risk is that the antiviral regimen loses its effect and human immunodeficiency virus (HIV) becomes resistant to the drugs (cobicistat summary of product characteristics, SmPC, European Medicines Agency, EMA, and label, US Food and Drug Administration, FDA). Laboratory tests, not how the person feels, show a loss of virologic response (cobicistat FDA label).
Management
The combination is contraindicated. Phenobarbital is on the cobicistat contraindication list together with carbamazepine and phenytoin. As strong CYP3A inducers, they can lower the levels of cobicistat and of the drug it boosts, and treatment may lose its effect (cobicistat summary of product characteristics, SmPC, European Medicines Agency, EMA, and cobicistat label, US Food and Drug Administration, FDA). The same contraindication appears in the SmPCs of the combination tablets of cobicistat with darunavir, atazanavir and elvitegravir (SmPCs of these products, EMA). The phenobarbital SmPC does not name cobicistat, but it contraindicates atazanavir, one of the two drugs that cobicistat is taken with (phenobarbital SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, and cobicistat SmPC, EMA). For a person taking cobicistat, choose seizure treatment without phenobarbital, carbamazepine or phenytoin (cobicistat SmPC, EMA, and FDA label). No document gives an interval between stopping phenobarbital and starting cobicistat. Do not stop phenobarbital abruptly; reduce the dose gradually (phenobarbital SmPC, AEMPS). Before starting cobicistat and during treatment, consider possible interactions, review all concomitant medicines and monitor for their adverse effects (cobicistat FDA label).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- EMA: Ficha técnica: Cobicistat (EU/1/13/872), sección 4.5 (2026)– EMA, Tybost 150 mg (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 113872001, consultada 10/2026, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Fenobarbital (nº registro 35052), sección 4.3 (2025)– AEMPS, CIMA, nº registro 35052 (Luminal 100 mg comprimidos, Kern Pharma), revisión 07/2025 (texto de marzo de 2025), secciones 4.2, 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Atazanavir/cobicistat, Evotaz (EU/1/15/1025), sección 4.3 (2026)– EMA, Evotaz 300 mg/150 mg comprimidos (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151025001, consultada 10/2026, sin fecha de revisión en CIMA, secciones 4.3 y 4.5
- EMA: Ficha técnica: Darunavir/cobicistat (EU/1/14/967), sección 4.3 (2026)– EMA, Rezolsta 800 mg/150 mg (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 114967001, consultada 10/2026, sección 4.3
- FDA: TYBOST (cobicistat) prescribing information (2026)– FDA, DailyMed setid 3784c35c-e87f-410c-900b-8fd6313c6010 (Gilead Sciences), versión 16 (SPL 10.02.2026, publicada 18.02.2026), secciones 4, 5.3, 7.1 y 7.3 (Table 7)
- EMA: Ficha técnica: Cobicistat, Tybost (EU/1/13/872), sección 4.3 (2026)– EMA, Tybost 150 mg comprimidos recubiertos con película (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 113872001, consultada 20.10.2026, sin fecha de revisión en CIMA, secciones 4.2, 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Elvitegravir/cobicistat/emtricitabina/tenofovir alafenamida, Genvoya (EU/1/15/1061), sección 4.3 (2026)– EMA, Genvoya 150 mg/150 mg/200 mg/10 mg comprimidos recubiertos con película (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151061001, consultada 20.10.2026, sin fecha de revisión en CIMA, secciones 4.3 y 4.5
- EMA: Ficha técnica: Darunavir/cobicistat/emtricitabina/tenofovir alafenamida, Symtuza (EU/1/17/1225), sección 4.5 (2026)– EMA, Symtuza 800 mg/150 mg/200 mg/10 mg comprimidos recubiertos con película (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1171225001, consultada 21.10.2026, sin fecha de revisión en CIMA, secciones 4.3 y 4.5